期刊文献+

生长激素型垂体腺瘤患者的骨密度研究 被引量:2

Bone mineral density of patients with growth hormone secreting pituitary adenomas
下载PDF
导出
摘要 目的:评估中国大陆生长激素腺瘤患者的骨代谢改变并进一步分析其影响因素.方法:选取2007-12/2008-07间于我院就诊的生长激素腺瘤患者23(男9,女14)例和同期的健康对照组244例,对患者组的骨密度改变进行评估.并依据患者术前的激素水平,分析生长激素腺瘤患者术前骨密度的影响因素.结果:生长激素腺瘤患者的骨密度Z值明显高于正常对照组.男性患者组的Z值较对照组明显升高,女性患者组的骨密度Z值的均值虽然高于其相应的对照组,但无统计学差异.Logistic回归分析的结果显示生长激素水平的升高和骨密度增加之间无明显的相关性.性腺功能减退组患者的骨密度Z值的均值低于无性腺功能减退组的患者,但无统计学差异.结论:生长激素腺瘤患者易出现骨密度的增高.其骨密度的改变是多种影响因素共同作用的结果. AIM:To evaluate the bone metabolic alteration of patients with growth hormone secreting pituitary adenoma(GH adenoma) in Chinese mainland and further to investigate the relevant factors leading to the change of bone mineral density(BMD).METHODS:Twenty-three patients with GH adenoma(9 men and 14 women) and 244 healthy controls were enrolled in this study between December 2007 and July 2008 and the BMD of the patients were assessed.The hormonal activities of the preoperative patients were analyzed to reveal the influencing factors of BMD.RESULTS:The Z scores of BMD of the patients with GH adenoma were significantly higher than those of corresponding controls.Compared with the Z scores of male controls,the ones of male patients significantly increased.However,there was not a statistical difference of Z scores between female patients and its controls.Logistic regression analysis revealed that there was not a significant correlation between BMD of the patients and serum growth hormone.The mean Z score of hypogonadal group was lower than that of eugonadal group,but no statistical difference existed between them.CONCLUSION:The BMD of patient with GH adenoma often increases,and the interaction of multiple factors is involved in the change of BMD.
出处 《第四军医大学学报》 北大核心 2009年第23期2848-2850,共3页 Journal of the Fourth Military Medical University
关键词 生长激素腺瘤 肢端肥大症 骨密度 growth hormone secreting pituitary adenomas acromegaly bone mineral density
  • 相关文献

参考文献11

  • 1Bolanowski M, Daroszewski J, Medras M, et al. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal fnnction[J]. J Bone Miner Metab, 2006, 24(1 ) :72 -78.
  • 2Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly-a potential beneficial effect of growth hormone [ J ]. Osteoporos Int, 2004, 15(2) :155 -159.
  • 3Matsuyama J, Eshima N, Fukunaga T, et al. Various risks of osteo- porosis in patients with pituitary adenomas [J]. J Bone Miner Metab, 2003, 21(2) :91 -97.
  • 4Tutuncu NB, Erhas T. Factors associated with bone metabolism in acromegalic patients : Hypogonadism and female gender [ J ]. Exp Clin Endoerinol Diabetes, 2004, 112(6):328-332.
  • 5Kayath M J, Vieira JG. Osteopenia occurs in a minodty of patients with acromegaly and is predominant in the spine[J]. Osteoporos Int, 1997, 7(3) :226 -230.
  • 6Ho PJ, Fig LM, Barkan AL, et al. Bone mineral density of the axial skeleton in acromegaly [J]. Nucl Med, 1992, 33 ( 9 ) : 1608 - 1612.
  • 7Zqliczynski W, Kochman M, Misiorowski W, et al. In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender [ J ]. Neuro Endocrinol Lett, 2007, 28(5) :621 -628.
  • 8Chiodini I, Trischitta V, Carnevale V, et al, Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis?[J]. J Endocrinol Invest, 2001, 24(4) :288 -291.
  • 9Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly [ J ]. J Clin Endocrinol Metab, 2008, 93(12) :4649 -4655.
  • 10Kayath MJ, Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine [ J ]. Osteoporos Int, 1997, 7(3) :226 -230.

同被引文献17

  • 1吴莹,陶天遵.雄激素与男性骨质疏松症[J].中国骨质疏松杂志,2006,12(2):201-203. 被引量:6
  • 2Matsuyama J,Eshima N,Fukunaga T,et al.Various risks of osteoporosis in patients with pituitary adenornas.J Bone Miner Metab,2003,21:91-97.
  • 3Kanis JA,Melton LJ 3rd,Christiansen C,et al.The diagnosis of osteoporosis.J Bone Miner Res,1994,9:1137-1141.
  • 4Zadrozna-Sliwka B,Bolanowski M,Kaluzny M,et al.Bone mineral density and bone turnover in hyperprolactinaemia of various origins.Endokrynol Pol,2007,58:116-122.
  • 5Torring O,Isberg B,Sj(o)berg HE,et al.Plasma calcitonin,IGFI levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment.Acta Endocrinol,1993,128:423-427.
  • 6Rozhinskaia LIa,Marova EI,Dzeranova LK,et al.Bone tissue in patients with hyperprolactinemic hypogonadism.Probl Endokrinol(Mosk),1992,38:17-19.
  • 7Colao A,Di Somma C,Loche S,et al.Prolactinomas in adolescents:persistentbonelossafter2yearsofprolactin normalization.Clin Endocrinol(Oxf),2000,52:319-327.
  • 8Seeman E.The structural and biomechanical basis of the gain and loss of bone strength in women and men.Endocrinol Metab Clin North Am,2003,32:25-38.
  • 9朱慧锋,王珠美,王维佳.骨质疏松症相关基因的研究进展[J].实用医学杂志,2008,24(11):1863-1864. 被引量:9
  • 10代洪宾,张伟滨.雄激素、雌激素与男性骨质疏松症[J].国际骨科学杂志,2009,30(2):121-123. 被引量:34

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部